Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04445935|
Recruitment Status : Unknown
Verified June 2020 by Dr. Marcus Daniel Lance, Hamad Medical Corporation.
Recruitment status was: Recruiting
First Posted : June 24, 2020
Last Update Posted : June 24, 2020
Patients with COVID-19 associated ARDS and mechanical ventilation have a high mortality. Part of the disease is an activation of the coagulation system which seems to contribute to clotformation in the pulmonary bloodstream. Recently we implemented an algorithm applying higher doses of heparins (LMWH). However, this approach could not inhibit clotformation enough. Bivalirudin could prevent clotformation better and support dissolving existing clots.
Therefore, we want to compare 50 patients with the standard treatment with 50 patients under bivalirudin treatment which we normally apply in patients with a HIT-syndrome.
Our primary outcome measure is oxygenation reflected as P/F ratio.
|Condition or disease||Intervention/treatment||Phase|
|Anticoagulation in COVID-19 ARDS||Drug: Bivalirudin Injection Drug: Standard treatment||Phase 4|
The pandemic of COVID-19, a newly upcoming viral disease caused by SARS-CoV-2, puts the whole worlds health system under pressure.
Patients suffering from this disease mainly develop respiratory symptoms, which can lead to severe acute respiratory distress syndrome (ARDS) necessitating ICU admission in 10-20% of the cases admitted to hospital. In addition to these symptoms, patients show lymphopenia, cardiac symptoms and altered coagulation profiles. Although those patients are treated in the ICU the mortality there is more than 20% due to multiorgan failure.
One of the recent insights in this disease is its effect on the coagulation system. Meanwhile we know that the coagulation system gets activated. Furthermore, it seems that clot formation takes place in the pulmonary micro-vasculature which could contribute to the widely observed gas-exchange impairment. Therefore, many centers apply empiric anticoagulation for their COVID-patients. At the moment, we at HMC, also apply an empirical anticoagulation protocol as our standard approach. However, this is a symptomatic treatment without good proof.
Bivalirudin is a well-known agent which is used in HMC for cases in which anticoagulation is needed, but a contraindication for heparin exists (i.e. HIT syndrome). This drug has an interesting pharmacologic profile. It acts independent of antithrombin (AT), the physiological compound which enhances heparin effects under normal circumstances. This lack of dependence on AT, makes Bivalirudin an attractive choice in light of the contradictory reports on the levels of AT during COVID infection. If AT levels are decreased during the infection, heparin (as well as LMWH) cannot work efficiently, which would render our treatment less effective. Luckily, bivalirudin acts without the support of AT, so we could bypass this problem. In addition, bivalirudin has some fibrinolytic activities. It inhibits clot-bound thrombin which as a result destabilizes the clot rendering it more susceptible to thrombolysis. This property partially supports the dissolving of clots and could support re-opening the pulmonary microcirculation.
To prove the positive effect of anticoagulation with bivalirudin intravenously on gas-exchange in patients with COVID-19 and respiratory failure on invasive mechanical ventilation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||This is a randomized controlled trial.|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Masking Description:||This study will be blinded to the above mentioned group. The PI is not involved in active treatment. Patients are sedated and ventilated when treatment starts and finally the outcome assessors will not be knowing the patients treatment.|
|Primary Purpose:||Supportive Care|
|Official Title:||Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial|
|Estimated Study Start Date :||June 28, 2020|
|Estimated Primary Completion Date :||September 28, 2020|
|Estimated Study Completion Date :||March 28, 2021|
Active Comparator: Standard treatment
In this arm the patients will be treated according to our standard anticoagulation protocol.
The patients will not be treated with Bivalirudin (the investigational drug).
Drug: Standard treatment
This group will receive standard anticoagulation with LMWH/UFH
Experimental: Bivalirudin arm
The patients will be anticoagulated according to the institutional HIT-protocol which uses Bivalirudin as anticoagulant.
Drug: Bivalirudin Injection
The patients will receive iv Bivalirudin according to the institutional HIT protocol.
Other Name: anticoagulation
- P/F ratio [ Time Frame: three days of intervention ]the P/F ratio is a surrogate parameter for oxygenation in ARDS.
- Kidney function [ Time Frame: three days of intervention ]The kidney function frequently is deteriorated in COVID-19 patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04445935
|Contact: Marcus Lance, MD, PhD||00974 ext firstname.lastname@example.org|
|Contact: Stefan Roehrig, MD, MBA||00974 ext email@example.com|
|Hamad Medical Corporation||Recruiting|
|Contact: Nadir Kharma, MD 00974 ext 55118621 firstname.lastname@example.org|
|Principal Investigator:||Marcus Lance, MD, PhD||HMC|